99%+ HPLC Pure | Batch-Specific Third-Party COAs | Free Shipping Over $250

Kynetide Research Team | 21 hours ago

Peptide Reconstitution 101: Bacteriostatic Water, Dilution Math & Storage

Reconstituting a lyophilized peptide correctly is one of the most important steps in any research protocol. Use too much or too little bacteriostatic water, and your concentration math (and your results) can be thrown off before you even start. Here's a clear walkthrough of the process our research team follows.

Why Reconstitution Accuracy Matters

Lyophilized peptides are stable in powder form, but the moment bacteriostatic water is added, the clock starts on both stability and concentration accuracy. Adding the wrong volume of water throws off the final concentration, which then throws off every downstream calculation for dosing volumes in a research protocol. Small errors in reconstitution compound quickly, so it pays to slow down and get the math right before drawing anything into a syringe.

Bacteriostatic Water and Basic Dilution Math

The basic formula is straightforward: total peptide (mg) divided by total water added (mL) gives you the concentration in mg/mL. For example, adding 2 mL of bacteriostatic water to a 5 mg vial yields a 2.5 mg/mL solution. From there, a standard insulin syringe marked in units (where 100 units equals 1 mL) makes it easy to draw an exact dose once the concentration is known. Always double check the math on paper before drawing up a dose, and use a fresh calculation any time the water volume changes.

A Step-by-Step Reconstitution Walkthrough

Start by letting a refrigerated vial and the bacteriostatic water reach room temperature before mixing, which helps the powder dissolve smoothly. Insert the needle into the water vial, draw the calculated volume, then inject it into the peptide vial by aiming the stream along the inside wall of the glass rather than directly onto the powder. Gently swirl the vial to dissolve the peptide completely; do not shake it, since vigorous agitation can damage the peptide's structure. Once fully dissolved, the solution should generally look clear, and any persistent cloudiness is worth double-checking before use.

Storing Reconstituted Peptides

Once a peptide is reconstituted, it should generally move straight into a refrigerator rather than sitting at room temperature. Most reconstituted peptides hold up best when used within a few weeks, though exact stability windows vary by compound, so it's worth checking guidance specific to what you're working with. Keep the vial away from light, label it with the reconstitution date, and avoid repeated temperature swings from taking it in and out of the fridge more than necessary.

A Quick Reconstitution Checklist

Before reconstituting, confirm the peptide amount printed on the vial, calculate the exact water volume needed for your target concentration, and have alcohol swabs, a clean syringe, and bacteriostatic water ready. During mixing, add water slowly along the vial wall and swirl gently rather than shaking. Afterward, label the vial with the date and concentration, refrigerate it promptly, and record your dosing calculations somewhere you can reference later. A consistent routine here removes most of the guesswork from every future draw.

Let’s create what matters — together.

Kynetide Research Team

More Posts

How to Read a Peptide COA: A Researcher's Guide to Certificates of AnalysisHow to Read a Peptide COA: A Researcher's Guide to Certificates of Analysis
How to Read a Peptide COA: A Researcher's Guide to Certificates of Analysis

A Certificate of Analysis (COA) is the single most important document that comes with a research peptide order, yet it's also one of the most overlooked. Knowing how to read one — and what to look for — turns an unfamiliar lab report into a clear signal of quality and identity. Here's a practical breakdown of what every COA should tell you.

How to Travel With Research Peptides: Cold-Chain Storage & Transport Guide (2026)How to Travel With Research Peptides: Cold-Chain Storage & Transport Guide (2026)
How to Travel With Research Peptides: Cold-Chain Storage & Transport Guide (2026)

Relocating for a conference, shipping samples between labs, or just moving vials from the freezer to the bench: every step outside cold storage puts peptide integrity at risk. Here's what our research team looks at when planning safe transport for temperature-sensitive compounds.

What's Really in Your Compounded GLP-1?What's Really in Your Compounded GLP-1?
What's Really in Your Compounded GLP-1?

This week's reporting on compounded GLP-1 products raises a question that goes beyond weight-loss injections: how do you know a compounded peptide is chemically what it claims to be? Stanford Medicine clinicians and independent lab analyses are documenting real gaps — unapproved salt forms, undisclosed additives, and even newly formed molecules that don't exist in the approved drug. Here's what the research actually found, and why verified sourcing is the real answer.

Patient Safety Groups Are Sounding the Alarm on the FDA's Peptide VotePatient Safety Groups Are Sounding the Alarm on the FDA's Peptide Vote
Patient Safety Groups Are Sounding the Alarm on the FDA's Peptide Vote

While everyone's been focused on which peptides made this week's FDA advisory vote, a quieter story has been unfolding alongside it: the agency's own scientists recommended against every peptide under review, and now patient safety groups are formally warning that the panel's decision came without the evidence needed to justify it. Here's what ECRI, ISMP, and the Partnership for Safe Medicines actually said, and what it means for anyone buying peptides today.

The Peptide Safety Gap Nobody's Watching Is at Your Local Med SpaThe Peptide Safety Gap Nobody's Watching Is at Your Local Med Spa
The Peptide Safety Gap Nobody's Watching Is at Your Local Med Spa

While everyone's been watching the FDA's advisory committee vote, a new Washington Post investigation points to a bigger, quieter risk: the medspas and wellness clinics actually injecting peptides into consumers face less regulatory oversight than your neighborhood restaurant. Here's what the investigation found, why the gap exists, and what it means for anyone buying peptides today.

The Peptide Headlines Don't Match the PaperworkThe Peptide Headlines Don't Match the Paperwork
The Peptide Headlines Don't Match the Paperwork

For months, social media has insisted that Robert F. Kennedy Jr. already "legalized" a wave of popular research peptides. This week's FDA advisory committee vote added fuel to that story, but the actual paper trail tells a more complicated tale. Here's what's really changed, what's still just talk, and what it means if you're buying peptides today.

Six Peptides In, One Rejected: What the FDA Vote Really ChangesSix Peptides In, One Rejected: What the FDA Vote Really Changes
Six Peptides In, One Rejected: What the FDA Vote Really Changes

This week's FDA Pharmacy Compounding Advisory Committee meeting ended with six peptides recommended for the agency's 503A Bulk Drug Substances List and one turned away. The vote made headlines, but the fine print matters more than the tally. Here is what the committee actually decided, what it does not decide, and why sourcing still matters no matter how the FDA rules.

FDA Peptide Vote Sends Hims & Hers Shares Higher as Wall Street Eyes a Multi-Billion Dollar MarketFDA Peptide Vote Sends Hims & Hers Shares Higher as Wall Street Eyes a Multi-Billion Dollar Market
FDA Peptide Vote Sends Hims & Hers Shares Higher as Wall Street Eyes a Multi-Billion Dollar Market

An FDA advisory panel's split vote on peptide compounding sent Hims & Hers Health shares swinging Thursday, as Wall Street analysts weighed a potential multi-billion dollar telehealth opportunity against lingering safety concerns raised by the agency's own scientists.

Behind the FDA Peptide Vote: MAHA Allies, Industry Ties, and a Political FightBehind the FDA Peptide Vote: MAHA Allies, Industry Ties, and a Political Fight
Behind the FDA Peptide Vote: MAHA Allies, Industry Ties, and a Political Fight

Politico's reporting on this week's FDA advisory vote reveals a story bigger than which peptides made the list. It shows a panel reshaped by new appointees, FDA scientists warning they have no guardrails left to apply, and a lobbying fight that now moves to Secretary Robert F. Kennedy Jr.'s desk.